August 2 2017: FDA emails show disagreements about a drug called eteplirsen. Some experts said it didn’t work well enough, but it was approved anyway, raising safety concerns. The National Center for Health Research says this shows the need for better rules to protect patients.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Drug Puts A $750,000 ‘Price Tag On Life’
FDA Panel Supports Licensing Two-Dose Hep B Vaccine
Cigarette Maker Stocks Plunge on FDA Announcement, But Health Experts Are Skeptical
Marketwatch, July 28 2017: The FDA proposed lowering nicotine in cigarettes to make them non-addictive. Stocks fell, but experts worry about delays in regulating e-cigarettes, cigars, and other tobacco products. Health advocates are concerned that postponing the planned reviews for these products could keep harmful items on the market longer, harming public health.
Read More »The Battle Over Essure
The Washington Post, July 26, 2017: Essure was marketed as an easy, non-invasive permanent contraception (sterilization), but many women reported pain, serious harm requiring surgery, and pregnancies. It wasn’t until patients and public health experts like NCHR met with FDA officials that the agency added warnings. Some women needed surgery to remove the device, and lawsuits claimed FDA approved Essure based on poorly conducted clinical trials.
Read More »